Pacific Biosciences Appoints John F. Milligan to Board of Directors
News Jul 30, 2013
Pacific Biosciences of California, Inc. announced that John F. Milligan, Ph.D. has joined the Company's Board of Directors. Dr. Milligan currently serves as President and Chief Operating Officer of Gilead Sciences.
Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.
Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. In 2008, Dr. Milligan joined the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization. Dr. Milligan is a Trustee of Ohio Wesleyan University. He received his BA from Ohio Wesleyan University, his Ph.D. in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.
"John is a prominent and well-respected figure in the biotechnology industry, and we are delighted to have him join our Board of Directors," said Michael Hunkapiller, CEO and Chairman of the Board of Directors of Pacific Biosciences. "The combination of scientific and business expertise he brings will be a valuable addition to PacBio."
Dr. Milligan commented: "I'm very pleased to join the Board of Pacific Biosciences, and I look forward to working with my fellow directors and the senior management team to further the company's mission of delivering tools and technology that are helping to drive scientific and medical innovation."
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019
4th Annual Congress on Nanomedicine and Drug Delivery
Apr 04 - Apr 06, 2019